Abstract
The purpose of the study was to investigate effects of roflumilast on the level of control, systemic inflammation markers, general and mucosal humoral anti-endotoxin immunity in patients with asthma–COPD overlap syndrome (ACOS). Methods. Forty patients with ACOS were involved. All the patients were treated with a standard therapy. Of them, 20 patients received roflumilast additionally during 1 month. Clinical parameters were analyzed using ACQ Elizabeth Juniper questionnaire, mMRC scale and spirometry. Anti-endotoxin antibodies A, M, G classes and C-reactive protein were measured by ELISA. Results. Additional administration of roflumilast significantly improved control of the disease, reduced systemic inflammation and improved mucosal anti-endotoxin immunity in patients ACOS with neutrophil inflammation. Six-month follow-up showed that the effect prolonged in 15.8% of the patients. Conclusion. Efficacy and duration of effects of roflumilast in ACOS patients requires further research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
